A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS9110-TPS9110
◽
Keyword(s):
Phase 2
◽